SG160386A1 - Novel composition - Google Patents
Novel compositionInfo
- Publication number
- SG160386A1 SG160386A1 SG201001631-9A SG2010016319A SG160386A1 SG 160386 A1 SG160386 A1 SG 160386A1 SG 2010016319 A SG2010016319 A SG 2010016319A SG 160386 A1 SG160386 A1 SG 160386A1
- Authority
- SG
- Singapore
- Prior art keywords
- influenza
- relates
- preparation
- pandemic outbreak
- novel composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010022000 influenza Diseases 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229960003971 influenza vaccine Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant. No accompanying figure.
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0506000A GB0506000D0 (en) | 2005-03-23 | 2005-03-23 | Novel use |
| GB0506001A GB0506001D0 (en) | 2005-03-23 | 2005-03-23 | Novel use |
| GB0506004A GB0506004D0 (en) | 2005-03-23 | 2005-03-23 | Compositions |
| GB0505989A GB0505989D0 (en) | 2005-03-23 | 2005-03-23 | Compositions |
| GB0510593A GB0510593D0 (en) | 2005-05-24 | 2005-05-24 | Novel compositions |
| GB0510596A GB0510596D0 (en) | 2005-05-24 | 2005-05-24 | Composition |
| GB0510598A GB0510598D0 (en) | 2005-05-24 | 2005-05-24 | Composition |
| GB0510589A GB0510589D0 (en) | 2005-05-24 | 2005-05-24 | Novel use |
| GB0510591A GB0510591D0 (en) | 2005-05-24 | 2005-05-24 | Novel use |
| GB0603789A GB0603789D0 (en) | 2006-02-24 | 2006-02-24 | Novel use |
| GB0603788A GB0603788D0 (en) | 2006-02-24 | 2006-02-24 | Novel composition |
| GB0603790A GB0603790D0 (en) | 2006-02-24 | 2006-02-24 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG160386A1 true SG160386A1 (en) | 2010-04-29 |
Family
ID=42269948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG201001631-9A SG160386A1 (en) | 2005-03-23 | 2006-03-21 | Novel composition |
Country Status (1)
| Country | Link |
|---|---|
| SG (1) | SG160386A1 (en) |
-
2006
- 2006-03-21 SG SG201001631-9A patent/SG160386A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200722101A (en) | Novel composition | |
| MX2009000660A (en) | Influenza vaccine. | |
| Honda-Okubo et al. | Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses | |
| Garçon et al. | Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion | |
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| Banzhoff et al. | MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis | |
| NZ594482A (en) | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant | |
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| WO2008112344A3 (en) | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins | |
| Sanders et al. | Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines | |
| Parodi et al. | Inactivated influenza vaccines: recent progress and implications for the elderly | |
| Garg et al. | Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain | |
| BRPI0621886A8 (en) | monovalent influenza vaccine composition, kit, method for producing an influenza vaccine composition for a pandemic or prepandemic situation, and uses of an influenza virus antigen or antigen preparation thereof and an adjuvant in an oil-in-water emulsion, a pandemic influenza virus antigen or antigen preparation of the influenza virus hemagglutinin antigen, a pandemic influenza virus or antigenic preparation thereof, and an oil-in-emulsion adjuvant water and an antigen or antigen preparation of a first strain of influenza | |
| Boado | Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant | |
| BR112014023283A8 (en) | IMMUNOGENIC COMPOSITION, SECOND IMMUNOGENIC COMPOSITION, AND METHOD FOR PREVENTION AND/OR TREATMENT AGAINST INFLUENZA DISEASE | |
| Brown | The role of adjuvants in vaccines for seasonal and pandemic influenza | |
| SG160386A1 (en) | Novel composition | |
| WO2021216560A3 (en) | Vaccine compositions for sars-related coronaviruses and methods of use | |
| Morelli et al. | ISCOMATRIX adjuvant in the development of prophylactic and therapeutic vaccines | |
| SG139618A1 (en) | Influenza vaccine | |
| CY1115921T1 (en) | Flu vaccine | |
| WO2005023295A3 (en) | Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use | |
| Fisher et al. | Adjuvanted vaccines against influenza in the elderly | |
| WO2024068265A3 (en) | Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof | |
| MX2021010194A (en) | Adjuvanted multivalent influenza vaccines. |